Literature DB >> 18096708

Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial.

Vandack Nobre1, Stephan Harbarth, Jean-Daniel Graf, Peter Rohner, Jérôme Pugin.   

Abstract

RATIONALE: The duration of antibiotic therapy in critically ill patients with sepsis can result in antibiotic overuse, increasing the risk of developing bacterial resistance.
OBJECTIVES: To test the hypothesis that an algorithm based on serial measurements of procalcitonin (PCT) allows reduction in the duration of antibiotic therapy compared with empirical rules, and does not result in more adverse outcomes in patients with severe sepsis and septic shock.
METHODS: In patients randomly assigned to the intervention group, antibiotics were stopped when PCT levels had decreased 90% or more from the initial value (if clinicians agreed) but not before Day 3 (if baseline PCT levels were <1 microg/L) or Day 5 (if baseline PCT levels were >/=1 microg/L). In control patients, clinicians decided on the duration of antibiotic therapy based on empirical rules.
MEASUREMENTS AND MAIN RESULTS: Patients assigned to the PCT group had 3.5-day shorter median duration of antibiotic therapy for the first episode of infection than control subjects (intention-to-treat, n = 79, P = 0.15). In patients in whom a decision could be taken based on serial PCT measurements, PCT guidance resulted in a 4-day reduction in the duration of antibiotic therapy (per protocol, n = 68, P = 0.003) and a smaller overall antibiotic exposure (P = 0.0002). A similar mortality and recurrence of the primary infection were observed in PCT and control groups. A 2-day shorter intensive care unit stay was also observed in patients assigned to the PCT group (P = 0.03).
CONCLUSIONS: Our results suggest that a protocol based on serial PCT measurement allows reducing antibiotic treatment duration and exposure in patients with severe sepsis and septic shock without apparent harm.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18096708     DOI: 10.1164/rccm.200708-1238OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  166 in total

1.  Adoption of a High-Impact Innovation in a Homogeneous Population.

Authors:  Curtis H Weiss; Julia Poncela-Casasnovas; Joshua I Glaser; Adam R Pah; Stephen D Persell; David W Baker; Richard G Wunderink; Luís A Nunes Amaral
Journal:  Phys Rev X       Date:  2014-10-15       Impact factor: 15.762

2.  Use of procalcitonin (PCT) to guide discontinuation of antibiotic use in an unspecified sepsis is an antimicrobial stewardship program (ASP).

Authors:  Y X Liew; M P Chlebicki; W Lee; L Y Hsu; A L Kwa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-29       Impact factor: 3.267

Review 3.  An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients.

Authors:  Dimitrios K Matthaiou; Georgia Ntani; Marina Kontogiorgi; Garyfallia Poulakou; Apostolos Armaganidis; George Dimopoulos
Journal:  Intensive Care Med       Date:  2012-04-27       Impact factor: 17.440

Review 4.  Meta-analysis and systematic review of procalcitonin-guided therapy in respiratory tract infections.

Authors:  Hui Li; Yi-Feng Luo; Timothy S Blackwell; Can-Mao Xie
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

5.  The search for diagnostic markers in sepsis: many miles yet to go.

Authors:  Carolyn S Calfee; Jérôme Pugin
Journal:  Am J Respir Crit Care Med       Date:  2012-07-01       Impact factor: 21.405

Review 6.  Use of plasma procalcitonin levels as an adjunct to clinical microbiology.

Authors:  David N Gilbert
Journal:  J Clin Microbiol       Date:  2010-04-26       Impact factor: 5.948

7.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

Review 8.  Urosepsis--Etiology, Diagnosis, and Treatment.

Authors:  Nici Markus Dreger; Stephan Degener; Parviz Ahmad-Nejad; Gabriele Wöbker; Stephan Roth
Journal:  Dtsch Arztebl Int       Date:  2015-12-04       Impact factor: 5.594

9.  Clinical outcomes and costs associated with procalcitonin utilization in hospitalized patients with pneumonia, heart failure, viral respiratory infection, or chronic obstructive pulmonary disease.

Authors:  Stacy Aric Johnson; Austin Bernard Rupp; Kirsten Leigh Rupp; Santosh Reddy
Journal:  Intern Emerg Med       Date:  2021-01-16       Impact factor: 3.397

10.  New approaches to sepsis: molecular diagnostics and biomarkers.

Authors:  Konrad Reinhart; Michael Bauer; Niels C Riedemann; Christiane S Hartog
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.